Ratings by Rothschild Redburn (Simon Baker)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/3/2026 | Moderna | MRNA | Downgrade | Sell (Neutral) |
154.27 (200.10) |
29.71% | Details | |
| 9/16/2025 | Novo Nordisk | NVO | Upgrade | Buy (Neutral) |
55.62 (39.05) |
-29.79% | Details | |
| 9/12/2025 | Gilead Sciences | GILD | Maintain | Buy (N/A) |
|
Details | ||
| 8/14/2025 | Regeneron Pharma | REGN | New Coverage | Buy (N/A) |
556.55 (805.02) |
44.64% | Details | |
| 11/15/2024 | Autolus Therapeutics plc | AUTL | Upgrade | Buy (Neutral) |
3.29 (1.54) |
-53.19% | Details |
